💊 Medication
PCSK9 inhibitors
Injectable cholesterol drugs (evolocumab, alirocumab). Strong evidence they cut LDL ~50–60% and reduce cardiovascular events, and they modestly lower lipoprotein(a). The feared cognitive harm from very low LDL was directly tested and NOT found — they appear cognitively safe.
4 well-supported · 0 disputed. This shows how settled each sub-question is, not whether PCSK9 inhibitors is "good." Direction lives in each claim below.
The 4 claims about PCSK9 inhibitors
Each keeps its own verdict — we never average them away.
Are PCSK9 inhibitors safe for memory and thinking?
Strong support Yes, on the evidence so far. The worry that driving LDL cholesterol very low with PCSK9 inhibitors might harm the brain has not held up: dedicated trials tracking memory and cognition found no meaningful decline. Very low LDL from these drugs looks cognitively safe.
Do PCSK9 inhibitors like evolocumab and alirocumab substantially lower LDL cholesterol?
Strong support Yes, unequivocally — monoclonal PCSK9 antibodies cut LDL cholesterol by roughly 50-60% on top of statins, one of the most reproducible drug effects in lipidology.
Do PCSK9 inhibitors lower lipoprotein(a), the genetically-driven risk lipid?
Strong support Yes — evolocumab and alirocumab reduce Lp(a) by roughly 20-30%, a modest but real effect (smaller than for LDL and not enough to fully normalize high Lp(a)).
Do the injectable cholesterol drugs (PCSK9 inhibitors) actually prevent heart attacks and strokes?
Strong support Yes; large randomized trials show evolocumab and alirocumab cut major cardiovascular events ~15-25%, with the clearest benefit in high-risk and secondary-prevention patients.
Educational only, not medical advice. Hub descriptions are curated for honesty; see the methodology.